The Sputnik V COVID-19 Vaccine: Promising Interim Results Published

In a large randomized Russian trial, this combined recombinant adenovirus vaccine demonstrated a protective efficacy of 91.6% against SARS-CoV-2 infection.

Among the few licensed COVID-19 vaccines worldwide, one was approved by the Russian government during the summer of 2020; however, no supporting efficacy data were presented at that time. Now, preliminary results of a large phase 3 clinical trial have been published in a peer-reviewed journal. The vaccine, called Gam-COVID-Vac (also known as Sputnik V), employs a combination of two adenovirus vectors, Ad5 and Ad26, into which the SARS-CoV-2 full-length glycoprotein S gene was inserted.

In this randomized, double-blind trial involving adults without evidence of prior immunity to SARS-CoV-2, participants received two intramuscular injections of vaccine or placebo 21 days apart. Between September 7 and November 24, 2020, some 22,000 subjects we…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

The Sputnik V COVID-19 Vaccine: Promising Interim Results Published

Topics

Reviewing Author